Navigation Links
Orexigen(R) Therapeutics Names Michael Narachi, 24-Year Biopharmaceutical Veteran, New President and Chief Executive Officer
Date:3/31/2009

Inc., a private pharmaceutical company. In 2004, Narachi retired as an officer and Vice President and General Manager of Amgen's Anemia Business. Throughout his 20 years at Amgen, Narachi held various positions including: Product Development Team Leader for NEUPOGEN(R); Director of Clinical Operations in Thousand Oaks, Calif., and Cambridge, U.K.; Vice President of Development and Representative Director for Amgen Japan; Head of Corporate Strategic Planning; Chief Operations Officer of Amgen BioPharma; and Vice President, Licensing and Business Development. He is also a director of AMAG Pharmaceuticals, Inc.

Mr. Narachi received B.S. and M.A. degrees in Molecular Genetics from the University of California at Davis. He also received an M.B.A. from the Anderson Graduate School of Management at University of California, Los Angeles.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the Company can be found at http://www.orexigen.com.

Forward-Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward-looking statements. These statements are
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Orexigen(R) Therapeutics Names Patrick Mahaffy to Board of Directors
2. Orexigen(R) Therapeutics to Speak at J.P. Morgan Healthcare Conference
3. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
4. Medarex Highlights Oncology Pipeline at Needham Cancer Therapeutics Conference in New York City
5. Oxygen Biotherapeutics, Inc. Establishes Warfighter Division
6. Transition Therapeutics Announces Initiation of a Phase Ib Clinical Study of TT-223 in combination with a GLP-1 analogue in Patients with Type 2 Diabetes
7. Poniard Pharmaceuticals to Present at Needham & Companys Cancer Therapeutics: Today & Tomorrow Conference
8. MRSA study suggests strategy shift needed to develop effective therapeutics
9. Cell Therapeutics, Inc. (CTI) President Craig Philips to Present at Invest Northwest
10. MPM Capital Leads Investment in Proteon Therapeutics
11. Cell Therapeutics Reschedules Special Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... a new electrophoretic method for detecting MIRCERA and ... technique, using SARCOSYL-PAGE, has specifically enhanced sensitivity for ... of SDS-PAGE for detecting other EPOs. Details ... the World Anti-Doping Agency (WADA), appear in the ... published by Wiley-Blackwell. , MIRCERA (methoxy polyethylene ...
(Date:12/15/2009)... 15 The Food and Health Bureau has ... overseas parties in developing private hospitals at four sites ... for submitting EOI is March 31, 2010. ,, ... Health, Dr. York Chow, said the promotion of private ... reform and a major Hong Kong government policy announced ...
(Date:12/15/2009)... 15 Vitech Systems Group, a leading ... (CRM) software, announced today that it has completed ... the Screen Actors Guild-Producers Pension & Health Plans ... service capabilities to SAG-PH call center personnel in ... installed using Vitech,s V3 Benefits Administration System which ...
(Date:12/15/2009)... Diabetes Association and the CDC have released some sobering statistics concerning ... States. Treadmill desks offer employers an effective means of combating this ... ... December 14, 2009 -- Rates of diabetes are climbing across America ... rates. Despite this rise the American Diabetes Association has stated that ...
(Date:12/15/2009)... Team In Training (TNT), The Leukemia & Lymphoma ... program, has reached a remarkable milestone of raising ... patient services. ,, For more than 21 years, ... training program, preparing amateurs and seasoned athletes to ... cycle ride or hike adventure. Through the program,s ...
Breaking Medicine News(10 mins):Health News:Researchers discover novel method for detecting MIRCERA 2Health News:Hong Kong Government Invites Expressions of Interest in Development of Private Hospitals 2Health News:Screen Actors Guild - Producers Pension & Health Plans Live on New CRM Solution 2Health News:TrekDesk: A Potentially Positive Impact on Diabetes & Obesity 2Health News:TrekDesk: A Potentially Positive Impact on Diabetes & Obesity 3Health News:$1 Billion - For Charity! 2Health News:$1 Billion - For Charity! 3
... developed at the University at Buffalo has killed every ... airborne spores, viruses and bacteria in independent tests conducted ... prototype produced by Buffalo BioBlower Technologies LLC, a UB ... better than one part per million in an independent ...
... Dental Experts to Advance ... of CCLAD in Dentistry, LIVINGSTON, N.J., Feb. 28 ... leader in,advanced injection technologies, today reported that earlier this ... (CCLAD) Summit in New Orleans. The Summit welcomed a ...
... Out of Poverty on Average Pays,for Itself and ... LOS ANGELES, Feb. 28 Close to ... today at the Milken,Institute for the West Coast ... the United States economy through proven,investments in children. ...
... motivates people to stay active, helps reduce arthritis ... pain ... announced today a,partnership with McNeil Consumer Healthcare, the maker of TYLENOL(R),Arthritis ... and reduce arthritis pain. Through this new collaboration,participating YMCAs will introduce ...
... was issued by The Mesothelioma Applied Research, Foundation ... House, Energy and Commerce Committee on the "Bruce Vento ... Thursday, February 28, 2008. The Meso,Foundation is urging the ... step-up to the plate in allocating research funds for ...
... Commission Director General for Enterprise & Industry Heinz Zourek today ... an EC budget of 624 million to ESA as a ... , This will be provided in two stages: 419 million ... the GSC programme. Segment 2 will be submitted for subscription ...
Other Medicine News:Health News:UB's bioblower closer to protecting soldiers from biological attack 2Health News:UB's bioblower closer to protecting soldiers from biological attack 3Health News:Milestone Scientific Hosts First International Computer-Controlled Local Anesthetic Delivery (CCLAD) Summit 2Health News:Milestone Scientific Hosts First International Computer-Controlled Local Anesthetic Delivery (CCLAD) Summit 3Health News:Milestone Scientific Hosts First International Computer-Controlled Local Anesthetic Delivery (CCLAD) Summit 4Health News:Milestone Scientific Hosts First International Computer-Controlled Local Anesthetic Delivery (CCLAD) Summit 5Health News:Business Leaders, Policy Makers and Advocates Gather to Discuss Strategies for Securing the Nation's Economy by Investing in Early Childhood 2Health News:Business Leaders, Policy Makers and Advocates Gather to Discuss Strategies for Securing the Nation's Economy by Investing in Early Childhood 3Health News:YMCA of the USA and McNeil Consumer Healthcare Partner to Promote Health for Older Adults 2Health News:YMCA of the USA and McNeil Consumer Healthcare Partner to Promote Health for Older Adults 3Health News:Leading Asbestos-Cancer Group Urges Congress to Partner with Them and Support Funding Provisions in Asbestos Ban Legislation 2Health News:Leading Asbestos-Cancer Group Urges Congress to Partner with Them and Support Funding Provisions in Asbestos Ban Legislation 3Health News:Space sentinels: New 'tools' in space to improve European environment and security policies 2Health News:Space sentinels: New 'tools' in space to improve European environment and security policies 3
(Date:12/15/2009)... Cellular Dynamics International ... iCell(TM) Cardiomyocytes for use in testing of new ... human heart cells are designed to aid drug ... efficacy and toxicity screens, weeding out ineffective and ... process before significant time and resources have been ...
(Date:12/15/2009)... PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI ... 15, 2009 special dividend payment of $1.67 per share ... December 1, 2009. With this payment, distributions to ... $2.67 per share. In January 2010, the Company ... of the Company,s 2009 cash distributions and the allocation ...
(Date:12/15/2009)... Dec. 15 The U.S. Food and Drug ... today voted 12 yes, 4 no, and 1 abstention ... observed risks to support the use of CRESTOR® (rosuvastatin ... Men greater than or equal to 50 years, women ... Fasting LDL < 130 mg/dL; hsCRP greater than or ...
Breaking Medicine Technology:Cellular Dynamics Announces Commercial Launch of iCell(TM) Cardiomyocytes for Drug Candidate Toxicity Screening 2Cellular Dynamics Announces Commercial Launch of iCell(TM) Cardiomyocytes for Drug Candidate Toxicity Screening 3Cellular Dynamics Announces Commercial Launch of iCell(TM) Cardiomyocytes for Drug Candidate Toxicity Screening 4PDL BioPharma Completes December 15 Special Dividend Payment 2Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 2Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 3Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 4Favorable Vote from FDA Advisory Committee on Benefit/Risk of CRESTOR(R) (rosuvastatin calcium) in JUPITER Study 5Teens Young Adults Need More Calcium 49403 1Teens Young Adults Need More Calcium 49403 2JourneyLite of Houston Receives Center of Excellence Accreditation 49400 1JourneyLite of Houston Receives Center of Excellence Accreditation 49400 2JourneyLite of Houston Receives Center of Excellence Accreditation 49400 3Childrens Named Among the Nations Top 10 Pediatric Hospitals by U S News 26 World Report 49396 1Childrens Named Among the Nations Top 10 Pediatric Hospitals by U S News 26 World Report 49396 2
... INC. (CBI) Prolactin ELISA kit is used ... human serum or plasma. Human prolactin (lactogenic ... with a molecular weight of approximately 23,000 ... a solid phase direct sandwich ELISA method. ...
... Prolactin ELISA Kit is enzyme immunoassay ... Human Prolactin (PRL) concentration in serum. ... quantitative determination of many protein hormones ... accurate, sensitive, reproducible, rapid and specific ...
... This Enzyme-Linked Immunosorbent Assay (ELISA) serves the ... from plasma, serum and,urine. In a 1 ... samples is bound to an,available excess of ... to the surface of the microtitre plates. ...
... The AxSYM BNP assay allows you ... the status of your heart due ... versus NT-ProBNP. The AxSYM BNP assay ... simple, walk-away resultson a platform that ...
Medicine Products: